Bifonazole

Summary

Bifonazole (CHEMBL277535) is an approved small molecule (ATC D01AC10); indicated across 2 conditions including tinea unguium and tinea pedis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D01AC10 (+1 more)
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 310.4 Da · C22H18N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL277535
Name	Bifonazole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2378
ChEBI	CHEBI:78692
ATC	D01AC10, D01AC60
Molecular formula	C22H18N2
Molecular weight	310.4
InChIKey	OCAPBUJLXMYKEJ-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)C2=CC=C(C=C2)C(C3=CC=CC=C3)N4C=CN=C4

IUPAC name: 1-[phenyl-(4-phenylphenyl)methyl]imidazole

ChEBI definition: A member of the class of imidazoles carrying an α-(biphenyl-4-yl)benzyl substituent at position 1.

Also known as: BAY H 4502, BAY-H-4502, Bifonazol, Bifonazole, D01AC10, Mycospor, NSC-758954, bifonazole, SID26719682, SID26747221, SID56422098, SID855867

Patent coverage: 3,462 distinct patent families (12,513 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 33 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Ubiquitin carboxyl-terminal hydrolase 2, Nuclear receptor ROR-gamma, Fructose-bisphosphate aldolase, Inositol monophosphatase 1, 4’-phosphopantetheinyl transferase ffp, Ferritin light chain, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Cysteine protease ATG4B, Amine oxidase [flavin-containing] A, Progesterone receptor, Menin/Histone-lysine N-methyltransferase MLL, Cannabinoid receptor 1, 5-hydroxytryptamine receptor 2A, Alpha-1A adrenergic receptor, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Cytochrome P450 3A4, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 21 potent at pChembl ≥ 5 of 47 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP17A1	7.25	Ki	56.5	nM	CHEMBL_ACT_1053575
CYP3A4	7	Potency	100	nM	CHEMBL_ACT_4973426
CYP3A4	7	Potency	100	nM	CHEMBL_ACT_5038651
CYP51A1	6.47	IC50	342	nM	CHEMBL_ACT_2122890
OPRK1	6.29	AC50	507.5	nM	CHEMBL_ACT_25129646
CYP3A4	6.1	IC50	800	nM	CHEMBL_ACT_17707402
CYP17A1	6.1	IC50	790	nM	CHEMBL_ACT_2227666
HSP90AA1	5.97	AC50	1064	nM	CHEMBL_ACT_7453971
HIF1A	5.9	Potency	1259	nM	CHEMBL_ACT_4128778
HIF1A	5.9	Potency	1259	nM	CHEMBL_ACT_4518571
KCNH2	5.68	AC50	2080	nM	CHEMBL_ACT_25118201
CNR1	5.53	AC50	2948	nM	CHEMBL_ACT_25181768
P97697	5.5	Potency	3162	nM	CHEMBL_ACT_4416071
MEN1	5.5	Potency	3162	nM	CHEMBL_ACT_4563357
P51450	5.5	Potency	3162	nM	CHEMBL_ACT_4991236
ADRA1A	5.37	AC50	4270	nM	CHEMBL_ACT_25138073
MAOA	5.1	AC50	7900	nM	CHEMBL_ACT_25159911
ATG4B	5.07	IC50	8500	nM	CHEMBL_ACT_5973164
ALDH1A1	5.05	Potency	8912	nM	CHEMBL_ACT_4143234
PLA2G1B	5.05	IC50	8890	nM	CHEMBL_ACT_7366383
P51450	5	Potency	10000	nM	CHEMBL_ACT_4794356

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
tinea unguium	3	MONDO:0001628	MONDO:0001628
tinea pedis	2	MONDO:0005984	EFO:0007512

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02705664	PHASE4	COMPLETED	Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1%

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).